The immunogenicity of two temperature-sensitive (ts) mutants of Pseudomonas aeruginosa immunotype 1, isolated and characterized for the development of a safe, live vaccine strain, was evaluated in a mouse protection model. One mutant, A/10/25, had a limited "coasting" property (i.e., continued replication for two divisions) at the nonpermissive temperature (36 degrees C), whereas the other mutant, E/9/9, continued replication for five generations after transfer to 36 degrees C. Groups of 3- to 5-week-old ICR mice were immunized intraperitoneally with various doses of the two ts mutants; at various times thereafter, the mice were challenged intraperitoneally with lethal doses of the parental wild type. The more extensive coaster, E/9/9, induced 100% protection at immunizing doses lower than those required for A/10/25 to induce the same protection (1 x 10(8) to 2 x 10(8) and 6 x 10(8) colony-forming units, respectively). Both ts strains induced significant protection for up to 5 weeks after immunization. The results of these studies suggest that the use of P. aeruginosa ts mutants might provide a novel approach to the prevention of P. aeruginosa colonization of patients with cystic fibrosis.
No takes yet. Share an insight, caveat, or question.
Hooke et al. (1982) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: